Bergstrom Eye Research — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$27,814	15
2023	Research	$136	1
2022	Research	$302,570	534
2021	Research	$29,961	58
2019	Research	$5,000	1

Breakdown

Who paid Research payments · program years 2019–2025

Alcon Research LLC $332,667 593 payments
Oyster Point Pharma, Inc. $27,814 15 payments
Mallinckrodt Enterprises LLC $5,000 1 payment

Studies the money was for Research payments · program years 2019–2025

Post Approval Study of the AcrySof IQ ReSTOR Toric IOL $307,731 583 payments
OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual Acuity (LYNX-3) $17,896 7 payments
A Phase 3 Study Evaluating the Safety and Efficacy of AR-15512, a Cold Thermoreceptor Modulator, for the Treatment of Dry Eye Disease (COMET-2) $17,500 3 payments
Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances (LYNX-2) $9,918 8 payments
A Multicenter, Open Label Pilot Study to Explore the Efficacy and Safety of H.P. Acthar Gel in Subjects With Severe Noninfectious Intermediate Uveitis, Posterior Uveitis, Or Panuveitis $5,000 1 payment
A Phase 3 Study Evaluating the Safety and Efficacy of AR-15512, a Cold Thermoreceptor Modulator, for the Treatment of Dry Eye Disease (COMET-2) $4,320 1 payment
Post Approval Study of the AcrySof IQ ReSTOR Toric IOLs $2,980 5 payments
A Phase 3 Study Evaluating the Safety and Efficacy of AR-15512, a Cold Thermoreceptor Modulator, for the Treatment of Dry Eye Disease (COMET-2) $136 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.